General Lung Cancer


Many Late Stage Lung Cancer Patients do not Receive Treatment (January 24, 2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from... Continue Reading

Keytruda® Data Demonstrating Activity in Mesothelioma Presented at 17th World Conference on Lung Cancer (January 3, 2017)

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) were featured in an oral presentation at the 17th World Conference on Lung Cancer hosted... Continue Reading

Keytruda® Active in Small Cell Lung Cancer (December 28, 2016)

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference... Continue Reading

Tagrisso®: New Standard of Care for Certain Lung Cancer (December 19, 2016)

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell... Continue Reading

Pass It On: It’s National Lung Cancer Awareness Month (November 2, 2016)

There are several types of lung cancer: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma and lung carcinoid tumors, with NSCLC and SCLC accounting for about 95% of diagnoses... Continue Reading

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (October 25, 2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of... Continue Reading

FDA Approves Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer (October 20, 2016)

Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer... Continue Reading

Patient Panel on Non-Small Cell Lung Cancer Addresses Key Issues (October 14, 2016)

Voices of Value Speak Up: Non-Small Cell Lung Cancer is the first part of a national six-event program presented by Patients Rising and Aimed Alliance. Where is the patient in the national conversation... Continue Reading

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (September 14, 2016)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The... Continue Reading

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer (September 13, 2016)

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors... Continue Reading

Keytruda® Demonstrates Superior Survival Compared to Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer (July 5, 2016)

Teatment with Keytruda® (pembrolizumab) for previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 is superior to standard chemotherapy. Lung cancer... Continue Reading

First Targeted Therapy Shows Promise in Small Cell Lung Cancer (June 7, 2016)

Small cell lung cancer (SCLC) accounts for approximately 20–25% of all lung cancers. SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial... Continue Reading

PD-1 Inhibitor Keytruda® Combined with Chemotherapy Promising in Lung Cancer Will be Evaluated in Larger Clinical Trials (June 6, 2016)

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, new data evaluating Keytruda® (pembrolizumab) in combination with chemotherapy appears promising... Continue Reading

Two-Drug Immunotherapy Deemed Safe for Small Cell Lung Cancer Patients, Moffitt Study Shows (June 6, 2016)

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive... Continue Reading

Xalkori® Approved for Lung Cancer with ROS-1 Gene Alterations (March 29, 2016)

The United States Food and Drug Administration (FDA) approved Xalkori (crizotinib) as treatment for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has an alteration within the ROS-1... Continue Reading

Alecensa® Delays Cancer Progression Longer Than Xalkori® in Certain Lung Cancers (March 3, 2016)

Interim results from a large clinical trial demonstrated that the targeted agent Alecensa® (alectinib) delays the progression of cancer for a longer period of time than Xalkori® (crizotinib) among patients... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS